CompletedNCT06510504
Efficacy of BNC210 in Acute, As-needed Treatment of Anxiety in Social Anxiety Disorder - 1
Researchers compared 225 mg BNC210 and placebo, tracking side effects to assess safety in adults with an anxiety condition.
Medication studyAges 18–65United States
Understand this study
What did researchers investigate?
Researchers compared 225 mg BNC210 and placebo, tracking side effects to assess safety in adults with an anxiety condition.
Who was this study for?
This study was for people with anxiety. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Encino, United States · La Jolla, United States and 18 more locationsSee all locations and recruitment
- Activities
- Medication described in the protocol · Placebo comparator
- Compensation
- Payment and expense reimbursement have not been verified.
Study information
Study start dateStarted: August 6, 2024
- Recruitment status
- Completed
- Enrollment listed in the registry
- 370
- Sponsor
- Bionomics Limited
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06510504
- Official title
Show the full official title
A Phase 3, Randomized, Double-blind, 2-arm, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of BNC210 for the Acute, As-needed Treatment of Anxiety in Adults With Social Anxiety Disorder
Recruitment & locations
CompletedEncino · La Jolla · Los Angeles
17 more locations
- Oceanside
- San Diego
- San Jose
- Sherman Oaks
- Temecula
- Jacksonville
- Lauderhill
- Miami Lakes
- Orlando
- Tampa
- Decatur
- Boston
- Princeton
- Brooklyn
- Charlotte
- Media
- Austin
Questions about this study
What did researchers investigate?
Researchers compared 225 mg BNC210 and placebo, tracking side effects to assess safety in adults with an anxiety condition.
Who is behind this study?
The study sponsor is Bionomics Limited.
Did this study involve medication?
Yes. The study involved medication, including 225 mg BNC210 and Placebo.
Who was this study for?
This study was for people with anxiety. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedNCT05729373
A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder
Researchers compared SEP-363856 and placebo to find out how the approaches affected anxiety symptoms in adults with an anxiety condition.
CompletedNCT05407064
A Dose-Finding Study of MM120 (LSD D-Tartrate) for Anxiety Symptoms
United States
CompletedNCT01996644
A Double Blind study of DCS for Food Anxiety
United States